Roche's Lebrikizumab Shows Potential For Biomarker Targeting In Asthma
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II data published in NEJM show that biomarker-assisted therapies could be valuable in targeting the variabilities of the disease.
You may also be interested in...
Personalized Medicine Takes Aim At Common Diseases
While oncology steals the limelight, some firms are harnessing the technologies and R&D strategies of precision medicine to develop combination drug/diagnostic products for large-population, non-oncology diseases.
Roche Believes Biomarker Could Position Antibody For Severe Asthma For Success
During an investor presentation Nov. 7, the Swiss pharma outlined its plans to move lebrikizumab into Phase III next year.
Roche Believes Biomarker Could Position Antibody For Severe Asthma For Success
During an investor presentation Nov. 7, the Swiss pharma outlined its plans to move lebrikizumab into Phase III next year.